Nikita Forghani
Pediatric Endocrinology · Orange, CANPI 1902011026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $756 and has fallen 53.0% since, to $355 in 2025.
Across 116 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$246
- Novo Nordisk$209
- Lilly USA, LLC$205
- Dexcom, Inc.$204
- Abbott$201
- Amphastar Pharmaceuticals, Inc.$146
- plus $2K from 28 others
Across 11 payments — averaging $5597.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$62K
What the payments were for
- Food & beverage$2,48892%
- Education$2258%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $246 |
| Novo Nordisk | 9 | $209 |
| Lilly USA, LLC | 10 | $205 |
| Dexcom, Inc. | 10 | $204 |
| Abbott | 3 | $201 |
| Amphastar Pharmaceuticals, Inc. | 8 | $146 |
| Tandem Diabetes Care, Inc. | 7 | $138 |
| AbbVie | 7 | $136 |
| Arbor Pharmaceuticals, Inc. | 6 | $121 |
| Ipsen Biopharmaceuticals, Inc | 3 | $110 |
| BETA Bionics, Inc. | 3 | $110 |
| Pfizer | 5 | $98 |
| Insulet Corporation | 4 | $94 |
| Eton Pharmaceuticals, Inc. | 2 | $70 |
| Companion Medical, Inc. | 2 | $54 |
| Amgen | 2 | $53 |
| Biomarin Pharmaceutical Inc. | 2 | $48 |
| AstraZeneca | 2 | $46 |
| Ascensia Diabetes Care US Inc. | 2 | $44 |
| Ascendis Pharma Endocrinology Inc | 1 | $42 |
| Tolmar Pharmaceuticals, Inc. | 1 | $42 |
| Vistapharm, Inc. | 2 | $38 |
| Mannkind Corporation | 2 | $30 |
| BD | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $24 |
| Travere Therapeutics, Inc. | 2 | $24 |
| Galen US Inc | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Embecta Corp. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $13 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,713 in reported general payments places this provider in the 65th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Orange
- Lynda PolgreenOrange$167K
- Timothy FlanneryOrange$32K
- Himala KashmiriOrange$5K
- Daina DreimaneOrange$3K
- Lien TrinhOrange$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Kevin KaisermanWest Covina$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.